ChitogenX Inc.
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regene… Read more
Market Cap & Net Worth: ChitogenX Inc. (CHNXF)
ChitogenX Inc. (OTCQB:CHNXF) has a market capitalization of $590.22K ($590.22K) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #41246 globally and #13419 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChitogenX Inc.'s stock price $0.01 by its total outstanding shares 83129520 (83.13 Million).
ChitogenX Inc. Market Cap History: 2022 to 2025
ChitogenX Inc.'s market capitalization history from 2022 to 2025. Data shows change from $13.72 Million to $590.22K (-72.63% CAGR).
ChitogenX Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChitogenX Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CHNXF by Market Capitalization
Companies near ChitogenX Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to ChitogenX Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ChitogenX Inc. Historical Marketcap From 2022 to 2025
Between 2022 and today, ChitogenX Inc.'s market cap moved from $13.72 Million to $ 590.22K, with a yearly change of -72.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $590.22K | +39.22% |
| 2024 | $423.96K | -89.15% |
| 2023 | $3.91 Million | -71.52% |
| 2022 | $13.72 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ChitogenX Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $590.22K USD |
| MoneyControl | $590.22K USD |
| MarketWatch | $590.22K USD |
| marketcap.company | $590.22K USD |
| Reuters | $590.22K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.